Category: EBITDA

analysis, analytics, Aphria, business, Business Analysis, CANADA, canadian, cannabis, Cannin, Cannin Commentary, cbd, commentary, compliance, cultivation, Cultivation & Growing, Dispensaries & Retail, dispensary, earnings, EBITDA, EU, europe, European, export, extraction, Federal, finance, financial, German, government, growing, holdings, import, industry, investing, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, Operations, product, Product Development, Q2, Quality, quarter, recreational, regulation, regulations, regulatory, report, reporting, results, retail, revenue, second, state, thc, Tilray

Is Tilray Stock a Buy Post Fiscal Q2 Results?

Is Tilray Stock a Buy Post Fiscal Q2 Results?

Canadian cannabis giant Tilray (NASDAQ:TLRY) announced its fiscal second quarter of 2022 results last week. The company reported net revenue of $155 […]

acquire, acquisition, analysis, analytics, Aphria, Ayr, business, Business Analysis, california, CANADA, cannabis, capital, cbd, Columbia Care, compliance, consumer, COVID, COVID-19, cultivation, curaleaf, Depreciation, dispensary, EBITDA, extraction, Federal, finance, financial, financing strategies, government, Grassroot, growing, growth, Health, holdings, industry, Institutional, Interest, invest, investor, law, legal, legalization, legalize, legislation, Liberty, license, marijuana, market, medical, medicine, merge, merger, MSO, multi, operator, product, Quality, recreational, regulation, regulations, regulatory, retail, Sciences, Select, short, state, strategies, taxes, term, thc, Tilray, Verano

Cannabis M&A in the Post-COVID Era

Cannabis M&A in the Post-COVID Era

After a slow start following a disappointing 2019, M&A in the cannabis space closed 2020 with a bang, with more than $600 […]